Salta al contenuto principale
Passa alla visualizzazione normale.

MARIO LATTERI

Vinorelbine plus cisplatinum for the treatment of Stage IIIB and IV Non Small Cell Lung Carcinoma.

  • Autori: Gebbia, V.; Caruso, M.; Valenza, R.; Testa, A.; Cannata, G.; Verderame, F.; Cipolla, C.; Curto, G.; Oliveri, D.; Chiarenza, M.; Latteri, M.; Di Gesù, G.; Gebbia, N.
  • Anno di pubblicazione: 1994
  • Tipologia: Articolo in rivista (Articolo in rivista)
  • OA Link: http://hdl.handle.net/10447/233837

Abstract

Thirty consecutive patients with stage IIIB-IV non small cell lung cancer were treated with a combination of cisplatin 80 mg/m2 on day 1 plus vinorelbine 25-30 mg/m2 on days 1, 8. This cycle was repeated every 3 weeks. The overall response rate was 46%, with 1 patient showing a complete response and 13 patients (43%) a partial response with a mean duration of 8.4+ months. Six patients had a stabilization and 10 progressed. The main toxicities were represented by myelosuppression and nausea/vomiting. Grade 3 leukopenia was seen in 33% of cases, grade 2 thrombocytopenia in 12%, and phlebitis in the injection vein in 16%. Mild constipation was also recorded. The combination of cisplatin plus vinorelbine is quite effective in advanced non small cell carcinoma of the lung, and may be safely given on an outpatient basis